SUTRO BIOPHARMA, INC. (STRO)

20.45 -4.04% (-0.86)

Over 5Y: -89.9%

2026-08-28
100 200
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '21 — Revenue: 8.5M Q3 '21 — Operating Cash Flow: -24.4M Q3 '21 — Net Income: -30.9M Q4 '21 — Revenue: 10.7M Q4 '21 — Operating Cash Flow: -21.6M Q4 '21 — Net Income: -38.1M Q1 '22 — Revenue: 5.9M Q1 '22 — Operating Cash Flow: -35.3M Q1 '22 — Net Income: -39.1M Q2 '22 — Revenue: 28.1M Q2 '22 — Operating Cash Flow: -3.2M Q2 '22 — Net Income: -26M Q3 '22 — Revenue: 25.1M Q3 '22 — Operating Cash Flow: 65.9M Q3 '22 — Net Income: -19.5M Q4 '22 — Revenue: 8.6M Q4 '22 — Operating Cash Flow: -23.9M Q4 '22 — Net Income: -34.6M Q1 '23 — Revenue: 12.7M Q1 '23 — Operating Cash Flow: -61M Q1 '23 — Net Income: -50M Q2 '23 — Revenue: 10.4M Q2 '23 — Operating Cash Flow: -31.2M Q2 '23 — Net Income: -38.5M Q3 '23 — Revenue: 16.9M Q3 '23 — Operating Cash Flow: -33.5M Q3 '23 — Net Income: -49.3M Q4 '23 — Revenue: 113.7M Q4 '23 — Operating Cash Flow: 14.1M Q4 '23 — Net Income: 31.1M Q1 '24 — Revenue: 13M Q1 '24 — Operating Cash Flow: -64.7M Q1 '24 — Net Income: -58.2M Q2 '24 — Revenue: 25.7M Q2 '24 — Operating Cash Flow: 9.5M Q2 '24 — Net Income: -48M Q3 '24 — Revenue: 8.5M Q3 '24 — Operating Cash Flow: -64.5M Q3 '24 — Net Income: -48.8M Q4 '24 — Revenue: 14.8M Q4 '24 — Operating Cash Flow: -71.7M Q4 '24 — Net Income: -72.4M Q1 '25 — Revenue: 17.4M Q1 '25 — Operating Cash Flow: -67.9M Q1 '25 — Net Income: -76M Q2 '25 — Revenue: 63.7M Q2 '25 — Operating Cash Flow: -44.7M Q2 '25 — Net Income: -11.5M Q3 '25 — Revenue: 9.7M Q3 '25 — Operating Cash Flow: -38.2M Q3 '25 — Net Income: -56.9M Q4 '25 — Revenue: 11.6M Q4 '25 — Operating Cash Flow: -26.4M Q4 '25 — Net Income: -46.8M Q1 '26 — Revenue: 14.5M Q1 '26 — Operating Cash Flow: -42.3M Q1 '26 — Net Income: -38.5M Q2 '26 — Revenue: 9.8M Q2 '26 — Operating Cash Flow: -38.3M Q2 '26 — Net Income: -38.5M -40M 0 40M 80M 120M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.6
SBC / sales 14.8%
OE margin -332.5%
Oper. margin -319.6%
Accruals -18.2%
EBITDA margin -306.3%
FCF margin -317.7%
OCF margin -317.7%
Profit margin -395.2%
ROA -92.9%
ROCE -103.2%
Capex / sales —
Gross margin —
OCF / EBIT —
ROE —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

2.2
RPO / sales 0.14×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.7
ND/EBITDA —
Cash runway 1.1 yr
Debt payback 0.0 yr
Quick ratio 3.3×
F-score 2.6 pts
Cash / Debt —
Debt / Eq —
Equity / Assets —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

3.2
Sales CAGR 4Y +13.4%
Sales/sh Y/Y -60.2%
Sales Q/Q -84.6%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.